These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 19828274

  • 1. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients.
    King P, Citron DM, Griffith DC, Lomovskaya O, Dudley MN.
    Diagn Microbiol Infect Dis; 2010 Feb; 66(2):181-6. PubMed ID: 19828274
    [Abstract] [Full Text] [Related]

  • 2. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, Macleod C, Aaron SD, Harbour C.
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [Abstract] [Full Text] [Related]

  • 3. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
    McCaughey G, McKevitt M, Elborn JS, Tunney MM.
    J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients.
    Traczewski MM, Brown SD.
    Antimicrob Agents Chemother; 2006 Feb; 50(2):819-21. PubMed ID: 16436756
    [Abstract] [Full Text] [Related]

  • 5. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Islam S, Oh H, Jalal S, Karpati F, Ciofu O, Høiby N, Wretlind B.
    Clin Microbiol Infect; 2009 Jan; 15(1):60-6. PubMed ID: 19154484
    [Abstract] [Full Text] [Related]

  • 6. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms.
    Field TR, White A, Elborn JS, Tunney MM.
    Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):677-87. PubMed ID: 16249934
    [Abstract] [Full Text] [Related]

  • 7. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA, Mauldin PD, Steed LL.
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [Abstract] [Full Text] [Related]

  • 8. [Discrepancy in the disk diffusion susceptibility test of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients after anaerobic preincubation and its potential clinical relevance].
    Cafini F, García-Rey C, Bas P, Gómez-Lus ML, Sánchez I, Vázquez S, Prieto J.
    Rev Esp Quimioter; 2012 Dec; 25(4):269-73. PubMed ID: 23303259
    [Abstract] [Full Text] [Related]

  • 9. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O.
    APMIS Suppl; 2003 Dec; (116):1-47. PubMed ID: 14692154
    [Abstract] [Full Text] [Related]

  • 10. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
    King P, Lomovskaya O, Griffith DC, Burns JL, Dudley MN.
    Antimicrob Agents Chemother; 2010 Jan; 54(1):143-8. PubMed ID: 19805554
    [Abstract] [Full Text] [Related]

  • 11. Anaerobic culture conditions favor biofilm-like phenotypes in Pseudomonas aeruginosa isolates from patients with cystic fibrosis.
    O'May CY, Reid DW, Kirov SM.
    FEMS Immunol Med Microbiol; 2006 Dec; 48(3):373-80. PubMed ID: 17052266
    [Abstract] [Full Text] [Related]

  • 12. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T, Petrova G, Mitov I.
    J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
    [Abstract] [Full Text] [Related]

  • 13. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
    Fernández-Olmos A, García-Castillo M, Maiz L, Lamas A, Baquero F, Cantón R.
    Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
    [Abstract] [Full Text] [Related]

  • 14. Oxygen, cyanide and energy generation in the cystic fibrosis pathogen Pseudomonas aeruginosa.
    Williams HD, Zlosnik JE, Ryall B.
    Adv Microb Physiol; 2007 Aug; 52():1-71. PubMed ID: 17027370
    [Abstract] [Full Text] [Related]

  • 15. Anaerobic physiology of Pseudomonas aeruginosa in the cystic fibrosis lung.
    Schobert M, Jahn D.
    Int J Med Microbiol; 2010 Dec; 300(8):549-56. PubMed ID: 20951638
    [Abstract] [Full Text] [Related]

  • 16. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F, Can F, Azap OK, Demirbilek M, Arslan H, Karaman SO.
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [Abstract] [Full Text] [Related]

  • 17. Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases.
    Holby N, Olling S.
    Acta Pathol Microbiol Scand C; 1977 Apr; 85(2):107-14. PubMed ID: 404841
    [Abstract] [Full Text] [Related]

  • 18. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin.
    Drago L, De Vecchi E, Nicola L, Tocalli L, Gismondo MR.
    J Antimicrob Chemother; 2005 Aug; 56(2):353-9. PubMed ID: 15967767
    [Abstract] [Full Text] [Related]

  • 19. Post-antibiotic effect of levofloxacin and tobramycin alone or in combination with cefepime against Pseudomonas aeruginosa.
    Ozbek B, Otuk G.
    Chemotherapy; 2009 Aug; 55(6):446-50. PubMed ID: 19996590
    [Abstract] [Full Text] [Related]

  • 20. Dynamics of adaptive microevolution of hypermutable Pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis.
    Hoboth C, Hoffmann R, Eichner A, Henke C, Schmoldt S, Imhof A, Heesemann J, Hogardt M.
    J Infect Dis; 2009 Jul 01; 200(1):118-30. PubMed ID: 19459782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.